Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn s disease.
Successful first-attempt peripheral intravenous cannulation in patients with difficult venous access can avoid delays in administering medications in the emergency department. Is bi-plane imaging the long-sought answer?